FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:1399-1401 October 9, 2003 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hughes, T. P. PubMed Citation

For many years hematologists have used the microscope to identify a complete remission of leukemia after treatment with chemotherapy. In a hematologic complete remission, we know that a large portion of the leukemic cells remain out of sight. These cells, invisible to the microscopist, are the components of an important clinical problem termed "minimal residual disease."

The concept of minimal residual disease and its detection and eradication were the topic of a special series of conferences held in Rotterdam, the Netherlands, in 1983 and subsequent years. In those days, we were beginning to see a substantial number of patients with . . . [Full Text of this Article]

Source Information

From Erasmus University Medical Center, Rotterdam, the Netherlands.

This article has been cited by other articles:

• Quintas-Cardama, A., Cortes, J. (2009). Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619-1630 [Abstract] [Full Text]  
• Motiwala, T., Majumder, S., Ghoshal, K., Kutay, H., Datta, J., Roy, S., Lucas, D. M., Jacob, S. T. (2009). PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells. J. Biol. Chem. 284: 455-464 [Abstract] [Full Text]  
• Quintas-Cardama, A., Cortes, J. (2008). Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia. Clin. Cancer Res. 14: 4392-4399 [Abstract] [Full Text]  
• Kawano, T., Ito, M., Raina, D., Wu, Z., Rosenblatt, J., Avigan, D., Stone, R., Kufe, D. (2007). MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells. Cancer Res. 67: 11576-11584 [Abstract] [Full Text]  
• Kometani, K., Aoki, M., Kawamata, S., Shinozuka, Y., Era, T., Taniwaki, M., Hattori, M., Minato, N. (2006). Role of SPA-1 in Phenotypes of Chronic Myelogenous Leukemia Induced by BCR-ABL-Expressing Hematopoietic Progenitors in a Mouse Model.. Cancer Res. 66: 9967-9976 [Abstract] [Full Text]  
• Tefferi, A., Dewald, G. W., Litzow, M. L., Cortes, J., Mauro, M. J., Talpaz, M., Kantarjian, H. M. (2005). Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. Mayo Clin Proc. 80: 390-402 [Abstract]  
• Tefferi, A. (2005). Introduction: Translating New Biology Into Clinical Practice. Mayo Clin Proc. 80: 61-62